Invasive Aspergillosis (IA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

In critically ill patients within the intensive care unit, including those with severe influenza and severe COVID-19 infection, Invasive Aspergillosis (IA) is increasingly recognized. While primarily affecting the lungs, aspergillosis can manifest in virtually any organ system, and disseminated disease is prevalent in patients with prolonged granulocytopenia following chemotherapy. Despite progress in diagnosing and treating IA, mortality rates remain elevated, especially in immunosuppressed individuals. Triazole resistance has emerged in some global regions, posing a significant concern for management due to limited options for treating azole-resistant infections and the potential for prophylaxis failure in immunocompromised hosts. Cryptic species of Aspergillus, which are morphologically challenging to identify, have gained importance due to higher azole antifungal minimum inhibitory concentrations (MICs), difficulty in differentiation based on appearance alone, and the uncertain clinical outcomes and therapeutic challenges they pose. With over 250 species of Aspergillus, various subgenera, and multiple sections, the most frequently isolated species in invasive disease cases are A. fumigatus, followed by A. flavus, A. terreus, and A. niger. While most Aspergillus species reproduce asexually, some may have a teleomorph (sexual) form. Aspergillus spp are ubiquitous in the environment, found in water, food, air, and soil, occupying a clear environmental niche.

Patients undergoing hematopoietic stem cell transplantation (HSCT) face the highest risk of IA, particularly invasive pulmonary aspergillosis (IPA) and sinus disease. Risk factors in this population include:

  1. Prolonged neutropenia
  2. Defects in cell-mediated immunity
  3. Extended immunosuppressive therapy for graft-versus-host disease (GVHD)

Individual patient risk varies based on the type of stem cell transplant (SCT), ranging from 0.5% to 3.9% among allogeneic transplant recipients, with lower rates in those receiving autologous SCT. IA is also prevalent among solid organ transplantation (SOT) recipients, especially lung transplant recipients. The clinical presentation of aspergillosis varies, depending on the site of involvement and the host's ability to mount a robust immune response. While the upper airways, trachea, bronchi, lung parenchyma, and contiguous structures are commonly affected, dissemination or infection can occur in any organ system. Clinical syndromes may be categorized into allergic manifestations, noninvasive saprophytic infections, semi-invasive syndromes, and invasive diseases.

  • Globally, over 800 million people suffer from invasive fungal infections (IFIs), with yearly death rates (1,660,000) surpassing those of malaria (445,000) and comparable to tuberculosis (1,700,000).

Thelansis’s “Invasive Aspergillosis (IA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Aspergillosis (IA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Invasive Aspergillosis (IA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Invasive Aspergillosis (IA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Invasive Aspergillosis (IA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more